ZNF581 Antibody

What is ZNF581 and why is it a target of interest for antibody research?

ZNF581 (Zinc Finger Protein 581) is a protein-coding gene product belonging to the Cys2-His2 (C2H2)-type zinc finger protein family of transcription factors. These proteins contain zinc finger motifs - small peptide domains with secondary structures stabilized by zinc ions bound to cysteine and/or histidine residues . ZNF581 has become a target of interest because zinc finger proteins play crucial roles in various biological processes including development, differentiation, metabolism, autophagy, senescence, epithelial-mesenchymal transition (EMT), and apoptosis .

The human ZNF581 protein has a molecular weight of approximately 22.01 kDa and is encoded by a gene located on chromosome 19 . Research interest in ZNF581 has increased as emerging data suggest potential roles for ZNF family proteins in cancer progression and other pathological conditions.

How do ZNF581 antibodies differ from other zinc finger protein antibodies?

ZNF581 antibodies are specifically designed to recognize the unique epitopes of the ZNF581 protein, distinguishing it from other zinc finger family members. While zinc finger proteins share structural similarities in their zinc finger domains, they differ significantly in other regions, which allows for the development of specific antibodies.

Available ZNF581 antibodies include both monoclonal (like PCRP-ZNF581-1A12) and polyclonal options, with varying applications . By comparison, antibodies for related proteins such as ZNF582, ZNF589, and ZNF585B target their respective unique protein structures .

The research significance of these differences becomes evident when examining the diverse roles of zinc finger proteins in disease processes. For instance, while ZNF582 has been identified as having tumor suppressive properties in clear cell renal cell carcinoma , and ZNF589 appears downregulated in breast cancer , the specific function of ZNF581 in these or other contexts requires precise antibody-based investigation to elucidate.

What are the validated applications for ZNF581 antibodies in molecular biology research?

ZNF581 antibodies have been validated for multiple applications crucial to molecular and cellular research:

The methodological approach for each application requires optimization specific to the chosen antibody. For example, the Elabscience ZNF581 Polyclonal Antibody (E-AB-52844) is recommended at dilutions of 1:50-1:300 for IHC and 1:5000-1:10000 for ELISA applications .

What is the optimal protocol for immunohistochemical detection of ZNF581 in formalin-fixed paraffin-embedded tissues?

For optimal immunohistochemical detection of ZNF581 in FFPE tissues, researchers should follow this methodological approach:

• Section Preparation: Cut 4-6 μm sections from FFPE blocks and mount on positively charged slides.

• Deparaffinization and Rehydration:

  • Xylene: 2 changes, 10 minutes each

  • 100% ethanol: 2 changes, 5 minutes each

  • 95%, 80%, 70% ethanol: 3 minutes each

  • Distilled water: 5 minutes

• Antigen Retrieval: This step is critical for ZNF581 detection. Based on protocols similar to those used for related zinc finger proteins:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 9.0)

  • Pressure cooker or microwave heating for 20-40 minutes at 95-100°C

  • Cool slides to room temperature (approximately 20 minutes)

• Endogenous Peroxidase Blocking: 3% H₂O₂ in methanol for 10 minutes

• Protein Blocking: 5% normal serum (matched to secondary antibody host) for 30 minutes

• Primary Antibody Incubation: Apply ZNF581 antibody at the optimized dilution (for example, E-AB-52844 at 1:50 dilution) and incubate at 4°C overnight or at room temperature for 60 minutes .

• Detection System:

  • Secondary antibody: 30 minutes at room temperature

  • HRP-streptavidin: 30 minutes at room temperature

  • DAB development: Monitor until optimal signal (typically 1-5 minutes)

• Counterstaining: Hematoxylin for 30 seconds

• Dehydration and Mounting:

  • 70%, 80%, 95% ethanol: 2 minutes each

  • 100% ethanol: 2 changes, 3 minutes each

  • Xylene: 2 changes, 5 minutes each

  • Mount with permanent mounting medium

IHC of human thyroid cancer tissue using ZNF581 Polyclonal Antibody has been successfully demonstrated at a dilution of 1:50, suggesting this as a starting point for optimization in similar tissues .

How should researchers optimize Western blot conditions for detecting ZNF581 protein?

Optimizing Western blot conditions for ZNF581 detection requires systematic adjustment of several parameters:

• Sample Preparation:

  • Extraction buffer selection: RIPA buffer with protease inhibitors for total protein; consider NP-40 buffer for nuclear proteins

  • Protein quantification: BCA or Bradford assay to ensure equal loading

  • Loading amount: Start with 20-40 μg of total protein, adjust based on expression level

• Electrophoresis Parameters:

  • Gel percentage: 12-15% for optimal resolution of ZNF581 (22.01 kDa)

  • Running conditions: 100-120V constant voltage for better resolution

• Transfer Optimization:

  • Membrane selection: PVDF recommended for stronger protein binding

  • Transfer method: Wet transfer at 100V for 1 hour or 30V overnight at 4°C

  • Transfer buffer: Consider adding SDS (0.1%) if experiencing incomplete transfer

• Blocking and Antibody Incubation:

  • Blocking solution: 5% non-fat dry milk in TBST or 5% BSA in TBST (for phospho-specific detection)

  • Primary antibody dilution: Begin with manufacturer's recommendation (typically 1:1000)

  • Incubation conditions: Overnight at 4°C with gentle rocking

• Detection System:

  • Secondary antibody: HRP-conjugated, matching the host species of primary antibody

  • Development method: ECL for standard detection; consider enhanced ECL systems for low abundance targets

• Controls and Validation:

  • Positive control: Lysate from tissue/cells known to express ZNF581

  • Molecular weight verification: Confirm band appears at approximately 22 kDa

  • Blocking peptide: Consider using for specificity validation

When troubleshooting, remember that ZNF581 is a nuclear protein, so nuclear extraction protocols may improve detection compared to whole cell lysates. Additionally, because ZNF581 has a relatively low molecular weight, extend the running time to improve separation from other small proteins.

What considerations are important when designing co-immunoprecipitation experiments with ZNF581 antibodies?

When designing co-immunoprecipitation (Co-IP) experiments to investigate ZNF581 interactions:

• Antibody Selection:

  • Choose antibodies specifically validated for IP applications, such as PCRP-ZNF581-1A12

  • Consider using different antibodies for IP and Western blot detection to avoid heavy/light chain interference

  • Confirm the antibody recognizes native (non-denatured) ZNF581

• Lysis Buffer Optimization:

  • Use gentle, non-denaturing buffers (e.g., NP-40 or Triton X-100 based)

  • Include protease inhibitors, phosphatase inhibitors, and DTT or β-mercaptoethanol

  • Test different salt concentrations (150-300 mM NaCl) to balance specificity with interaction maintenance

• Pre-clearing Strategy:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Consider including a control IgG pre-clearing step

• Experimental Controls:

  • IgG control: Same species/isotype as the IP antibody

  • Input control: 5-10% of lysate used for IP

  • Bead-only control: To identify proteins binding to beads non-specifically

• Cross-linking Considerations:

  • For transient interactions, consider mild crosslinking with DSP or formaldehyde

  • Adjust crosslinking conditions (time, temperature, reagent concentration) for optimal results

• Detection Strategy:

  • For suspected interaction partners, consider enrichment methods like mass spectrometry

  • For known interactions, design Western blot detection with specific antibodies

• Reverse Co-IP Validation:

  • Confirm interactions by performing reciprocal Co-IP (IP with antibody against suspected interacting protein, blot for ZNF581)

For ZNF581, which likely functions as a transcription factor, consider specifically investigating interactions with other transcription factors, chromatin modifiers, or DNA-binding proteins. Based on research on related zinc finger proteins, potential interactions with proteins involved in transcriptional regulation pathways would be especially relevant to examine.

How can ChIP-seq be optimized for studying ZNF581 genomic binding sites?

Chromatin Immunoprecipitation followed by sequencing (ChIP-seq) for ZNF581 requires careful optimization:

• Antibody Validation for ChIP:

  • Perform preliminary ChIP-qPCR at known or predicted binding sites

  • Ensure high enrichment compared to IgG control (>10-fold recommended)

  • Verify antibody specificity via knockdown/knockout controls

• Crosslinking Optimization:

  • Standard protocol: 1% formaldehyde for 10 minutes at room temperature

  • Consider dual crosslinking with DSG followed by formaldehyde for improved DNA-protein fixation

  • For zinc finger proteins specifically, test extended crosslinking times (15-20 minutes)

• Chromatin Fragmentation:

  • Sonication parameters: Optimize to achieve 200-500 bp fragments

  • Verify fragment size by agarose gel electrophoresis

  • Consider enzymatic fragmentation alternatives (MNase) for difficult samples

• IP Conditions:

  • Chromatin amount: Start with 25 μg per IP, adjust based on target abundance

  • Antibody amount: Typically 2-5 μg, titrate for optimal signal-to-noise ratio

  • Incubation time: Overnight at 4°C with rotation

• Sequencing Considerations:

  • Input control: Essential for peak calling algorithm normalization

  • Sequencing depth: Minimum 20 million reads for transcription factors

  • Read length: 50-75 bp single-end generally sufficient

• Bioinformatic Analysis Strategy:

  • Peak calling algorithm selection: MACS2 recommended for narrow peaks typical of transcription factors

  • Motif analysis: To identify ZNF581 binding motifs

  • Integration with transcriptomic data: To correlate binding with gene regulation

• Validation Approaches:

  • ChIP-qPCR validation of selected peaks

  • Reporter assays for functional validation of binding sites

  • EMSA to confirm direct binding

Based on studies of other zinc finger proteins, ZNF581 likely binds to specific DNA sequences through its zinc finger domains. Analyzing enriched motifs from ChIP-seq data could reveal the specific binding preferences of ZNF581, aiding in understanding its transcriptional regulatory functions.

What methodological approaches are recommended for investigating ZNF581's role in cancer progression?

To investigate ZNF581's potential role in cancer progression, researchers should consider these methodological approaches:

• Expression Analysis in Cancer Datasets:

  • Analyze TCGA and other cancer genomics databases for ZNF581 expression patterns

  • Perform survival analyses correlating expression with patient outcomes, similar to the approach used for ZNF581 in prostate cancer where it showed a hazard ratio of 3.220 (95% CI: 1.437-7.213; p=0.0049)

  • Compare expression across different cancer types and stages

• Tissue-Based Studies:

  • Immunohistochemical analysis of ZNF581 in tumor tissue microarrays

  • Correlation with clinicopathological parameters

  • Co-localization studies with known cancer markers

• Functional Studies in Cell Lines:

  • Gain/loss of function experiments:

    • Overexpression studies using expression vectors

    • Knockdown using siRNA/shRNA

    • CRISPR-Cas9 knockout models

  • Phenotypic assays:

    • Proliferation (MTT, BrdU incorporation)

    • Migration/invasion (wound healing, transwell assays)

    • Colony formation

    • Apoptosis (Annexin V/PI, TUNEL)

• Mechanistic Investigations:

  • Transcriptome analysis after ZNF581 modulation (RNA-seq)

  • Identification of downstream target genes (ChIP-seq)

  • Protein interaction studies (Co-IP, proximity labeling)

  • Signaling pathway analysis (Western blot for key pathway proteins)

• In Vivo Models:

  • Xenograft models with ZNF581-modulated cell lines

  • Patient-derived xenografts

  • Transgenic mouse models (if appropriate)

• Epigenetic Regulation Analysis:

  • DNA methylation analysis of ZNF581 promoter

  • Histone modification ChIP studies

  • Response to epigenetic-modifying drugs

This comprehensive approach draws inspiration from studies of related zinc finger proteins. For example, ZNF582 has been shown to inhibit clear cell renal cell carcinoma progression, with decreased expression correlating with higher tumor stage, grade, distant metastasis, and poor prognosis . Similarly, ZNF589 was found to be downregulated in breast cancer, with potential prognostic significance .

How should researchers approach integrating ZNF581 data with broader zinc finger protein family studies?

Integrating ZNF581 research within the broader context of zinc finger protein studies requires systematic approaches:

• Comparative Genomic Analysis:

  • Phylogenetic analysis of ZNF581 with related ZNF proteins

  • Synteny analysis across species to identify evolutionary conservation

  • Identification of paralogous relationships (e.g., ZNF524 is noted as an important paralog of ZNF581)

• Structural Comparison Methodology:

  • Domain architecture analysis across ZNF family

  • Protein structure prediction and comparison

  • DNA-binding motif comparison between related ZNFs

• Functional Redundancy Assessment:

  • Multi-gene knockdown/knockout experiments

  • Rescue experiments with related ZNF genes

  • Co-expression network analysis

• Shared Regulatory Mechanism Investigation:

  • Cross-ChIP analysis for binding site overlap

  • Shared transcriptional regulation analysis

  • Common protein interaction partners

• Systems Biology Approach:

  • Pathway enrichment analysis across ZNF family datasets

  • Network analysis to place ZNF581 in context

  • Integration of multi-omics data (transcriptomics, proteomics, epigenomics)

• Comparative Disease Association:

  • Meta-analysis of disease associations across ZNF family

  • Correlation analysis of expression patterns in disease contexts

  • Investigation of shared genetic variants affecting ZNF family function

This comparative approach enables researchers to contextualize findings about ZNF581 within the broader functional landscape of zinc finger proteins, potentially revealing shared mechanisms and distinct functional specializations.

What are the most common issues in ZNF581 antibody-based experiments and how should they be addressed?

Common challenges in ZNF581 antibody experiments and their methodological solutions include:

• Low Signal Intensity:

  • Causes: Low expression levels, inadequate antibody concentration, insufficient antigen retrieval

  • Solutions:

    • Increase antibody concentration or incubation time

    • Optimize antigen retrieval (try different buffers, pH, and heating times)

    • Use signal amplification systems (TSA, polymer detection)

    • Consider more sensitive detection methods (chemiluminescence for WB, fluorescence for IHC)

• High Background:

  • Causes: Non-specific binding, excessive antibody concentration, inadequate blocking

  • Solutions:

    • Increase blocking time or change blocking agent (BSA vs. serum vs. commercial blockers)

    • Reduce primary antibody concentration

    • Increase washing duration and number of washes

    • Pre-absorb antibody with non-specific proteins

    • Use monoclonal antibodies like PCRP-ZNF581-1A12 for higher specificity

• Multiple Bands in Western Blot:

  • Causes: Cross-reactivity, protein degradation, post-translational modifications

  • Solutions:

    • Verify with knockout/knockdown controls

    • Test multiple antibodies targeting different epitopes

    • Optimize protein extraction protocols to minimize degradation

    • Consider phosphatase treatment if bands represent phosphorylated forms

• Variable Results Between Experiments:

  • Causes: Inconsistent sample preparation, antibody batch variation

  • Solutions:

    • Standardize protocols rigorously

    • Validate each new antibody lot

    • Include consistent positive controls

    • Pool samples where appropriate to reduce biological variability

• Subcellular Localization Discrepancies:

  • Causes: Fixation artifacts, epitope masking, biological variability

  • Solutions:

    • Compare multiple fixation methods

    • Use cell fractionation plus Western blot to verify localization

    • Verify with fluorescent protein tagging in live cells

• Contradictory Results Between Different Antibodies:

  • Causes: Different epitopes, variable specificity

  • Solutions:

    • Validate with appropriate controls (recombinant protein, knockout samples)

    • Confirm findings with orthogonal methods (mass spectrometry)

    • Consider epitope locations and potential masking in native protein complexes

Each troubleshooting approach should be systematically documented, as optimization parameters for ZNF581 detection may vary between tissue types, fixation methods, and experimental conditions.

How can researchers validate the specificity of ZNF581 antibodies in their experimental systems?

Comprehensive validation of ZNF581 antibody specificity requires multiple complementary approaches:

• Genetic Manipulation Controls:

  • siRNA/shRNA knockdown: Reduction in signal proportional to knockdown efficiency

  • CRISPR/Cas9 knockout: Complete absence of specific signal

  • Overexpression: Increased signal intensity proportional to expression level

• Recombinant Protein Controls:

  • Western blot with purified recombinant ZNF581 protein

  • Peptide competition assay: Pre-incubation of antibody with immunizing peptide should abolish specific signal

  • Dot blot titration with purified protein to establish detection limits

• Cross-Reactivity Assessment:

  • Western blot analysis in tissues/cells with known ZNF581 expression patterns

  • Testing across species if the antibody is claimed to be cross-reactive

  • Testing in cells expressing related zinc finger proteins (especially paralog ZNF524)

• Multiple Antibody Concordance:

  • Compare results using antibodies targeting different epitopes (e.g., N-terminal vs. C-terminal)

  • Compare monoclonal (like PCRP-ZNF581-1A12) and polyclonal (like E-AB-52844) antibodies

  • Verify that antibodies show consistent localization patterns in ICC/IHC

• Orthogonal Technique Validation:

  • Correlation of protein expression with mRNA levels (qRT-PCR)

  • Mass spectrometry confirmation of immunoprecipitated proteins

  • RNA-protein correlation in public databases (e.g., TCGA)

• Application-Specific Validation:

  • For IHC: Include positive and negative control tissues

  • For IP: Verify pull-down efficiency and specificity by Western blot

  • For ChIP: Include IgG control and known non-target regions

• Full Antibody Characterization Report:

  • Document validation results systematically

  • Include lot number, concentration, and all experimental conditions

  • Consider publishing validation data as supplementary material

This thorough validation approach ensures that experimental findings attributed to ZNF581 truly reflect the biology of this specific zinc finger protein rather than artifacts or cross-reactivity with related proteins.

How might single-cell technologies advance our understanding of ZNF581 function in heterogeneous systems?

Single-cell technologies offer unprecedented opportunities to elucidate ZNF581 function in complex biological systems:

• Single-Cell RNA Sequencing (scRNA-seq) Applications:

  • Cell type-specific expression profiling of ZNF581 across tissues

  • Identification of co-expression networks at single-cell resolution

  • Trajectory analysis to map ZNF581 expression changes during cellular differentiation

  • Correlation with cell state markers to identify functional contexts

• Single-Cell Protein Analysis Methods:

  • Mass cytometry (CyTOF) with metal-conjugated ZNF581 antibodies

  • Single-cell Western blotting for protein expression heterogeneity

  • Imaging mass cytometry for spatial context of ZNF581 expression

  • Proximity ligation assay at single-cell level for protein interaction studies

• Single-Cell Multi-Omics Integration Strategies:

  • CITE-seq: Combined protein (including ZNF581) and RNA profiling

  • scATAC-seq with scRNA-seq: Correlating chromatin accessibility with ZNF581 expression

  • Cellular indexing of transcriptomes and epitopes (CITE) for surface marker correlation

• Spatial Transcriptomics Methodologies:

  • In situ sequencing to map ZNF581 expression in tissue context

  • Spatial proteomics to correlate with tissue microenvironment

  • Cell-cell interaction analysis based on spatial proximity

• Functional Single-Cell Approaches:

  • CRISPR perturbation followed by single-cell readouts (CROP-seq)

  • Live-cell imaging with endogenously tagged ZNF581

  • Single-cell ChIP-seq to map binding site heterogeneity

• Computational Analysis Frameworks:

  • Cell clustering algorithms to identify ZNF581-high populations

  • Pseudotime analysis to track ZNF581 regulation during cellular processes

  • Network inference at single-cell resolution

These approaches would be particularly valuable for studying ZNF581 in cancer contexts, where cellular heterogeneity is a major challenge. By understanding how ZNF581 expression and function varies across different cell types within a tumor, researchers could potentially identify specific populations where ZNF581 plays critical roles in disease progression or treatment response.

What considerations are important when developing ZNF581-targeted therapeutic approaches?

Developing therapeutic strategies targeting ZNF581 requires careful consideration of several methodological and biological factors:

• Target Validation Requirements:

  • Robust causal evidence linking ZNF581 to disease pathology

  • Verification in multiple model systems and patient-derived samples

  • Understanding of potential redundancy with other zinc finger proteins

  • Comprehensive risk-benefit analysis based on normal tissue expression

• Therapeutic Modality Selection Criteria:

  • Small molecule approaches: Identify druggable pockets or protein-protein interactions

  • Antisense oligonucleotides: Design for ZNF581 mRNA specificity

  • PROTAC technology: For targeted protein degradation

  • Gene therapy: For contexts requiring expression restoration

• Delivery System Considerations:

  • Tissue-specific targeting strategies

  • Nuclear delivery methods (for transcription factor targeting)

  • Bioavailability optimization

  • Blood-brain barrier penetration (for CNS applications)

• Specificity Assessment Methodology:

  • Off-target binding analysis (particularly other zinc finger proteins)

  • Whole-transcriptome analysis after treatment

  • Proteomics to identify unexpected protein alterations

  • Cellular phenotype screening in diverse cell types

• Predictive Biomarker Development:

  • Identification of patient populations likely to respond

  • Companion diagnostic development

  • Response prediction algorithms incorporating ZNF581 status

  • Monitoring strategies for treatment efficacy

• Resistance Mechanism Anticipation:

  • Compensatory pathway activation potential

  • Expression of ZNF family members with redundant functions

  • Epigenetic adaptations affecting target accessibility

  • Clonal selection pressures

When considering ZNF581 as a therapeutic target, researchers should note that zinc finger proteins like ZNF582 have demonstrated tumor suppressive functions in certain cancers , while others may promote cancer progression. Therefore, thorough characterization of ZNF581's specific role in each disease context is essential before therapeutic development.